MARKET

GERN

GERN

Geron Corp
NASDAQ
2.370
+0.030
+1.28%
After Hours: 2.360 -0.01 -0.42% 17:00 10/03 EDT
OPEN
2.380
PREV CLOSE
2.340
HIGH
2.420
LOW
2.305
VOLUME
2.19M
TURNOVER
0
52 WEEK HIGH
3.060
52 WEEK LOW
0.9899
MARKET CAP
895.43M
P/E (TTM)
-7.0077
1D
5D
1M
3M
1Y
5Y
Marathon Digital, Coinbase Global And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning after recording losses in the previous session. Here are some big stocks moving higher in today’s pre-market trading session.
Benzinga · 6d ago
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket
Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for Vurolenatide in short bowel syndrome.
Benzinga · 6d ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., September 22, 2022--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 901,950 shares of Geron common stock as inducements to newly hired employees in connection ...
Business Wire · 09/22 20:30
H.B. Fuller, Lennar And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded slightly higher this morning after recording losses in the previous session. Here are some big stocks moving higher in today’s pre-market trading session.
Benzinga · 09/22 11:27
Geron Corporation's (NASDAQ:GERN) Intrinsic Value Is Potentially 95% Above Its Share Price
Does the September share price for Geron Corporation ( NASDAQ:GERN ) reflect what it's really worth? Today, we will...
Simply Wall St. · 09/14 10:43
Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors
FOSTER CITY, Calif., September 08, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022.
Business Wire · 09/08 20:15
Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., September 01, 2022--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Gero...
Business Wire · 09/01 20:30
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/22 23:10
More
About GERN
Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.